New attack on tough head & neck cancers that come back
NCT ID NCT04754321
Summary
This early-stage trial is testing whether combining an immunotherapy drug called pembrolizumab with surgery and targeted radiation can better control head and neck cancers that have returned or didn't fully respond to previous treatments. The study aims to find the safest way to combine these treatments while seeing if they help keep the cancer from growing back locally. Researchers will enroll about 45 patients whose cancer is still considered removable by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.